Abu Dhabi, UAE: Burjeel Holdings reported AED2.79 billion (US$761 million) in revenue for the first half of 2026, a 4.4% year-on-year increase, while patient visits rose 9.9% to more than 3.7 million, reflecting sustained demand for specialized healthcare services across its network.
The healthcare group recorded a 24.6% increase in EBITDA (excluding one-off items) to AED517 million, driven by higher contributions from newly opened facilities, expanding community-based services, and continued cost optimization. During the second quarter, inpatient revenue increased 11.9%, supported by stronger surgical volumes and more complex clinical cases.
Click here to join our WhatsApp channel here
Burjeel also strengthened its advanced clinical capabilities during the period. Burjeel Medical City’s multi-organ transplant programme reached 86 cumulative transplants, while Burjeel Cancer Institute became the world’s first institution to administer camizestrant (Etcamah) in a clinical care setting using ctDNA-guided treatment. The group also launched a dedicated Sarcoma & Bone Center to expand care for rare and complex cancers.
The company continued expanding its network with a new Burjeel Medical Center in Dubai Silicon Oasis and Tajmeel’s flagship aesthetics and wellness centre in Jumeirah. It also entered strategic collaborations with Roswell Park Comprehensive Cancer Center to enhance oncology services and EDGE Group to provide integrated healthcare for employees and their families.
Dr Shamsheer Vayalil, Chairman and Chief Executive Officer of Burjeel Holdings, said “the results reflected the resilience of the group’s integrated healthcare platform. Accelerating patient activity during the second quarter has further reinforced our confidence in the structural demand for high-quality, specialised healthcare across the region.”
